Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey


Hacioglu M. B. , Kostek O., Karabulut S. , Tastekin D. , SEZGİN GÖKSU S., Alandag C., ...Daha Fazla

JOURNAL OF BUON, cilt.25, ss.1897-1903, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 25 Konu: 4
  • Basım Tarihi: 2020
  • Dergi Adı: JOURNAL OF BUON
  • Sayfa Sayıları: ss.1897-1903

Özet

Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting.